Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
Open accessAbstract
Myeloid-derived suppressor cells (MDSCs) have emerged as major regulators of immune responses in cancer and other pathological conditions. In recent years, ample evidence supports key contributions of MDSC to tumour progression through both immune-mediated mechanisms and those not directly associated with immune suppression. MDSC are the subject of intensive research with >500 papers published in 2015 alone. However, the phenotypic, morphological and functional heterogeneity of these cells generates confusion in investigation and analysis of their roles in inflammatory responses. The purpose of this communication is to suggest characterization standards in the burgeoning field of MDSC research.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Myeloid subsets include macrophages (CD163, CD68) and MDSCs (S100A8, S100A9, TREM1).
“clusters high in the monocyte marker CD14, which were further re-clustered into macrophages (CD163, CD68) and MDSCs (S100A8, S100A9, TREM1).”
From Multimodal Analysis of Composition and Spatial Architecture in Human Squamous Cell Carcinoma (2020) · cites this paper as Bronte et al., 2016
In “MDSC versus tumour-associated macrophages and neutrophils” (page unavailable), the paper identifies CD68 and CD163 as human macrophage-specific markers and contrasts macrophages’ low or absent S100A9 with tumour M-MDSCs. “Phenotypic markers to define MDSC” also discusses CD33 with S100A9 as a suggested, but not definitive, MDSC marker combination. The passages do not support S100A8 or TREM1 as MDSC markers, or establish that the cited marker list alone identifies MDSCs. (LLM, conf=0.88)
Experimental — accuracy not yet measuredMyeloid subsets include CD1C DCs, CLEC9A cells, Langerhans cells, AS DCs, plasmacytoid DCs, and migrating DCs.
“The remaining subsets were re-clustered into CD1C DCs (CD1C, CLEC10A), CLEC9A cells (CLEC9A, CADM1, XCR1), Langerhans cells (CD207, CD1A, S100B), AS DCs (AXL, IGFBP5, PPP1R14A), plasmacytoid DCs (CLEC4C, IL3RA), and migrating DCs (CCR7, CCL19) (Bronte et al., 2016, Kiss et al., 2018, Villani et al., 2017).”
From Multimodal Analysis of Composition and Spatial Architecture in Human Squamous Cell Carcinoma (2020) · cites this paper as Bronte et al., 2016
The Definition of MDSC and Phenotypic markers to define MDSC sections describe suppressor-cell subsets, not the six dendritic-cell clusters or their marker combinations in the citing sentence. Searches for the cluster names and distinctive markers, including CLEC9A and AXL/IGFBP5/PPP1R14A, found no passage addressing that classification. The cited paper therefore cannot verify this part of the multi-citation sentence. (LLM, conf=0.76)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Macrophage activation and polarization: nomenclature and experimental guidelines
Murray, P. J., Allen, J. E., Biswas, S. K., Fisher, E. A., Gilroy, D. W., Goerdt, S., Gordon, S., Hamilton, J. A., Ivashkiv, L. B., Lawrence, T., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.008 · Cited by 6,337 · see citing works
Self-citationMacrophage plasticity and polarization: in vivo veritas
Sica, A., & Mantovani, A. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59643 · Cited by 6,335 · see citing works
Self-citationTumor-Associated Macrophages: From Mechanisms to Therapy
Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089 · see citing works
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544 · see citing works
Self-citationPolarization of Tumor-Associated Neutrophil Phenotype by TGF-β: “N1” versus “N2” TAN
Fridlender, Z. G., Sun, J., Kim, S., Kapoor, V., Cheng, G., Ling, L. E., Worthen, G. S., & Albelda, S. Μ. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.06.017 · Cited by 3,382 · see citing works
The prognostic landscape of genes and infiltrating immune cells across human cancers
Gentles, A. J., Newman, A. M., Liu, C. L., Bratman, S. V., Feng, W., Kim, D., Nair, V. S., Xu, Y., Khuong, A., Hoang, C. D., et al. (2015) · Nature Medicine · doi:10.1038/nm.3909 · Cited by 3,097 · see citing works
Tissue-Resident Macrophage Enhancer Landscapes Are Shaped by the Local Microenvironment
Lavin, Y., Winter, D., Blecher-Gonen, R., David, E., Keren-Shaul, H., Merad, M., Jung, S., & Amit, I. (2014) · Cell · doi:10.1016/j.cell.2014.11.018 · Cited by 2,167 · see citing works
Noman, M. Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., Bronte, V., & Chouaib, S. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20131916 · Cited by 2,166 · see citing works
Self-citationThe Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
Kumar, V., Patel, S., Tcyganov, E., & Gabrilovich, D. I. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.01.004 · Cited by 2,008 · see citing works
Self-citationDeNardo, D. G., Brennan, D. J., Rexhepaj, E., Ruffell, B., Shiao, S. L., Madden, S. F., Gallagher, W. M., Wadhwani, N., Keil, S. D., Junaid, S. A., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8274.cd-10-0028 · Cited by 1,715 · see citing works
Spranger, S., Spaapen, R. M., Zha, Y., Williams, J., Meng, Y., Ha, T. T., & Gajewski, T. F. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006504 · Cited by 1,677 · see citing works
Subsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice
Youn, J., Nagaraj, S., Collazo, M. M., & Gabrilovich, D. I. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.8.5791 · Cited by 1,645 · see citing works
Self-citationMacrophages, innate immunity and cancer: balance, tolerance, and diversity
Mantovani, A., & Sica, A. (2010) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.01.009 · Cited by 1,484 · see citing works
Self-citationOncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function
Viale, A., Pettazzoni, P., Lyssiotis, C. A., Ying, H., Sánchez, N., Marchesini, M., Carugo, A., Green, T., Seth, S., Giuliani, V., et al. (2014) · Nature · doi:10.1038/nature13611 · Cited by 1,259 · see citing works
Movahedi, K., Guilliams, M., den Bossche, J. V., den Bergh, R. V., Gysemans, C. A., Beschin, A., BAETSELIER, P. D., & Ginderachter, J. A. V. (2008) · Blood · doi:10.1182/blood-2007-07-099226 · Cited by 1,234 · see citing works
Movahedi, K., Laoui, D., Gysemans, C. A., Baeten, M., Stangé, G. M., den Bossche, J. V., Mack, M., PIPELEERS, D. G., Veld, P. I. '., BAETSELIER, P. D., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4672 · Cited by 1,229 · see citing works
History of myeloid-derived suppressor cells
Talmadge, J. E., & Gabrilovich, D. I. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3581 · Cited by 1,148 · see citing works
Self-citationYang, L., DeBusk, L. M., Fukuda, K., Fingleton, B., Green-Jarvis, B., Shyr, Y., Matrisian, L. M., Carbone, D. P., & Lin, P. C. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.08.031 · Cited by 1,140 · see citing works
Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected
Marvel, D., & Gabrilovich, D. I. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80005 · Cited by 1,054 · see citing works
Self-citationGabrilovich, D., Ishida, T., Oyama, T., Ran, S., Kravtsov, V., Nadaf, S., & Carbone, D. P. (1998) · Blood · doi:10.1182/blood.v92.11.4150 · Cited by 1,048 · see citing works
Self-citationChalmin, F., Ladoire, S., Mignot, G., Vincent, J., Bruchard, M., Rémy-Martin, J.-P., Boireau, W., Rouleau, A., Simon, B., Lanneau, D., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40483 · Cited by 999 · see citing works
Cheng, P., Corzo, C. A., Luetteke, N., Yu, B., Nagaraj, S., Bui, M. M., Ortiz, M. L., Nacken, W. K. F., Sorg, C., Vogl, T., et al. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20080132 · Cited by 904 · see citing works
Self-citationTumor-Induced Tolerance and Immune Suppression Depend on the C/EBPβ Transcription Factor
Marigo, I., Bosio, E., Solito, S., Mesa, C., Fernández, A., Dolcetti, L., Ugel, S., Sonda, N., Bicciato, S., Falisi, E., et al. (2010) · Immunity · doi:10.1016/j.immuni.2010.05.010 · Cited by 854 · see citing works
Self-citationTumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells
Shojaei, F., Wu, X., Malik, A. K., Zhong, C., Baldwin, M. E., Schanz, S., Fuh, G., Gerber, H.-P., & Ferrara, N. (2007) · Nature Biotechnology · doi:10.1038/nbt1323 · Cited by 849 · see citing works
Sinha, P., Clements, V. K., Bunt, S. K., Albelda, S. M., & Ostrand-Rosenberg, S. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.2.977 · Cited by 847 · see citing works
Self-citationThe Terminology Issue for Myeloid-Derived Suppressor Cells
Gabrilovich, D. I., Bronte, V., Chen, S., Colombo, M. P., Ochoa, A. C., Ostrand‐Rosenberg, S., & Schreiber, H. W. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3037 · Cited by 834 · see citing works
Self-citationTumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells
Gallina, G., Dolcetti, L., Serafini, P., Santo, C. D., Marigo, I., Colombo, M. P., Basso, G., Brombacher, F., Borrello, I., Zanovello, P., et al. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28828 · Cited by 792 · see citing works
Self-citationRodrı́guez, P. C., Ernstoff, M. S., Hernandez, C., Atkins, M. B., Zabaleta, J., Sierra, R. A., & Ochoa, A. C. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-1921 · Cited by 774 · see citing works
Self-citationMechanism Regulating Reactive Oxygen Species in Tumor-Induced Myeloid-Derived Suppressor Cells
Corzo, C. A., Cotter, M. J., Cheng, P., Cheng, F., Kusmartsev, S. A., Sotomayor, E. M., Padhya, T. A., McCaffrey, T. V., McCaffrey, J. C., & Gabrilovich, D. I. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900092 · Cited by 765 · see citing works
Self-citationProstaglandin E2 Promotes Tumor Progression by Inducing Myeloid-Derived Suppressor Cells
Sinha, P., Clements, V. K., Fulton, A. M., & Ostrand‐Rosenberg, S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4174 · Cited by 756 · see citing works
Self-citationProinflammatory S100 Proteins Regulate the Accumulation of Myeloid-Derived Suppressor Cells
Sinha, P., Okoro, C., Foell, D., Freeze, H. H., Ostrand‐Rosenberg, S., & Srikrishna, G. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.7.4666 · Cited by 722 · see citing works
Self-citationKowanetz, M., Wu, X., Lee, J., Tan, M., Hagenbeek, T., Qu, X., Yu, L., Ross, J., Korsisaari, N., Cao, T., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1015855107 · Cited by 663 · see citing works
Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells
Molon, B., Ugel, S., Pozzo, F. D., Soldani, C., Zilio, S., Avella, D., Palma, A. D., Mauri, P., Monegal, A., Rescigno, M., et al. (2011) · The Journal of Experimental Medicine · doi:10.1084/jem.20101956 · Cited by 651 · see citing works
Self-citationTumor-associated neutrophils stimulate T cell responses in early-stage human lung cancer
Eruslanov, E. B., Bhojnagarwala, P. S., Quatromoni, J. G., Stephen, T. L., Ranganathan, A., Deshpande, C. G., Akimova, T., Vachani, A., Litzky, L. A., Hancock, W. W., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci77053 · Cited by 645 · see citing works
Myeloid-derived suppressor cell heterogeneity and subset definition
Peranzoni, E., Zilio, S., Marigo, I., Dolcetti, L., Zanovello, P., Mandruzzato, S., & Bronte, V. (2010) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.01.021 · Cited by 634 · see citing works
Self-citationDolcetti, L., Peranzoni, E., Ugel, S., Marigo, I., Fernández, A., Mesa, C., Geilich, M., Winkels, G., Traggiai, E., Casati, A., et al. (2009) · European Journal of Immunology · doi:10.1002/eji.200939903 · Cited by 568 · see citing works
Self-citationUgel, S., Sanctis, F. D., Mandruzzato, S., & Bronte, V. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80006 · Cited by 563 · see citing works
Self-citationSerafini, P., Carbley, R., Noonan, K. A., Tan, G. G. Y., Bronte, V., & Borrello, I. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0757 · Cited by 524 · see citing works
Self-citationIL-4-Induced Arginase 1 Suppresses Alloreactive T Cells in Tumor-Bearing Mice
Bronte, V., Serafini, P., Santo, C. D., Marigo, I., Tosello, V., Mazzoni, A., Segal, D. M., Staib, C., Löwel, M., Sutter, G., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.1.270 · Cited by 513 · see citing works
Self-citationYoun, J., Collazo, M. M., Shalova, I. N., Biswas, S. K., & Gabrilovich, D. I. (2011) · Journal of Leukocyte Biology · doi:10.1189/jlb.0311177 · Cited by 510 · see citing works
Self-citationHighfill, S. L., Rodrı́guez, P. C., Zhou, Q., Goetz, C. A., Koehn, B. H., Veenstra, R. G., Taylor, P. A., Panoskaltsis‐Mortari, A., Serody, J. S., Munn, D. H., et al. (2010) · Blood · doi:10.1182/blood-2010-06-287839 · Cited by 465 · see citing works
Self-citationHyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer
Nefedova, Y., Huang, M., Kusmartsev, S., Bhattacharya, R., Cheng, P., Salup, R., Jove, R., & Gabrilovich, D. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.1.464 · Cited by 464 · see citing works
Self-citationC/EBPβ is required for 'emergency' granulopoiesis
Hirai, H., Zhang, P., Dayaram, T., Hetherington, C. J., Mizuno, S.-I., Imanishi, J., Akashi, K., & Tenen, D. G. (2006) · Nature Immunology · doi:10.1038/ni1354 · Cited by 425 · see citing works
Mechanism of T Cell Tolerance Induced by Myeloid-Derived Suppressor Cells
Nagaraj, S., Schrum, A. G., Cho, H.-I., Celis, E., & Gabrilovich, D. I. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902661 · Cited by 418 · see citing works
Self-citationMyeloid‐derived suppressor cell heterogeneity in human cancers
Solito, S., Marigo, I., Pinton, L., Damuzzo, V., Mandruzzato, S., & Bronte, V. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12469 · Cited by 383 · see citing works
Self-citationDumitru, C. A., Moses, K., Trellakis, S., Lang, S., & Brandau, S. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1294-5 · Cited by 370 · see citing works
Self-citationTumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice
Lu, T., Ramakrishnan, R., Altiok, S., Youn, J. I., Cheng, P., Celis, E., Писарев, В. М., Sherman, S., Sporn, M. B., & Gabrilovich, D. I. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45862 · Cited by 365 · see citing works
Self-citationER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis.
Condamine, T., Kumar, V., Ramachandran, I. R., Youn, J.-I., Celis, E., Finnberg, N., El-Deiry, W. S., Winograd, R., Vonderheide, R. H., English, N. R., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci74056 · Cited by 365 · see citing works
Self-citationYoun, J. I., Kumar, V., Collazo, M. M., Nefedova, Y., Condamine, T., Cheng, P., Villagra, A., Antonia, S. J., McCaffrey, J. C., Fishman, M., et al. (2013) · Nature Immunology · doi:10.1038/ni.2526 · Cited by 350 · see citing works
Self-citationUmemura, N., Saio, M., Suwa, T., Kitoh, Y., Bai, J., Nonaka, K., Ouyang, G., Okada, M., Balázs, M., Ádány, R., et al. (2008) · Journal of Leukocyte Biology · doi:10.1189/jlb.0907611 · Cited by 347 · see citing works
Inhibition of tumor growth by elimination of granulocytes.
Pekarek, L. A., Starr, B., Toledano, A. Y., & Schreiber, H. W. (1995) · The Journal of Experimental Medicine · doi:10.1084/jem.181.1.435 · Cited by 340 · see citing works
Myeloid-derived suppressor cell development is regulated by a STAT/IRF-8 axis
Waight, J. D., Netherby, C. S., Hensen, M. L., Miller, A., Hu, Q., Liu, S., Bogner, P. N., Farren, M. R., Lee, K. P., Liu, K., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68189 · Cited by 322 · see citing works
Elkabets, M., Ribeiro, V. S. G., Dinarello, C. A., Ostrand‐Rosenberg, S., Santo, J. P. D., Apte, R. N., & Vosshenrich, C. A. J. (2010) · European Journal of Immunology · doi:10.1002/eji.201041037 · Cited by 319 · see citing works
Self-citationBronte, V., Wang, M. L., Overwijk, W. W., Surman, D. R., Pericle, F., Rosenberg, S. A., & Restifo, N. P. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.10.5313 · Cited by 312 · see citing works
Self-citationFridlender, Z. G., Sun, J., Mishalian, I., Singhal, S. K., Cheng, G., Kapoor, V., Horng, W.-H., Fridlender, G., Bayuh, R., Worthen, G. S., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031524 · Cited by 311 · see citing works
Raber, P. L., Thevenot, P., Sierra, R. A., Wyczechowska, D. D., Halle, D., Ramírez, M. E., Ochoa, A. C., Fletcher, M., Velasco, C., Wilk, A. M., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.28622 · Cited by 298 · see citing works
Self-citationLiu, T., Daniels, C. K., & Cao, S. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.08.014 · Cited by 296 · see citing works
Nagaraj, S., Youn, J., Weber, H., Iclozan, C., Lu, L. D., Cotter, M. J., Meyer, C. J., Becerra, C. R., Fishman, M., Antonia, S. J., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3272 · Cited by 286 · see citing works
Self-citationMDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy
Finke, J. H., Ko, J. S., Rini, B. I., Rayman, P. A., Ireland, J. L., & Cohen, P. A. (2011) · International Immunopharmacology · doi:10.1016/j.intimp.2011.01.030 · Cited by 281 · see citing works
TNF Counterbalances the Emergence of M2 Tumor Macrophages
Kratochvill, F., Neale, G. A. M., Haverkamp, J. M., de Velde, L.-A. V., Smith, A. M., Kawauchi, D., McEvoy, J. D., Roussel, M. F., Dyer, M. A., Qualls, J. E., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.08.033 · Cited by 278 · see citing works
Self-citationMao, Y., Sarhan, D., Steven, A., Seliger, B., Kiessling, R. W., & Lundqvist, A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0635 · Cited by 274 · see citing works
Thevenot, P., Sierra, R. A., Raber, P. L., Al-Khami, A. A., Trillo-Tinoco, J., Zarreii, P., Ochoa, A. C., Cui, Y. R., Valle, L. D., & Rodrı́guez, P. C. (2014) · Immunity · doi:10.1016/j.immuni.2014.08.015 · Cited by 254 · see citing works
Self-citationRORC1 Regulates Tumor-Promoting “Emergency” Granulo-Monocytopoiesis
Strauss, L., Sangaletti, S., Consonni, F. M., Szebeni, G. J., Morlacchi, S., Totaro, M. G., Porta, C., Anselmo, A., Tartari, S., Doni, A., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.07.006 · Cited by 204 · see citing works
Self-citationMandruzzato, S., Brandau, S., Britten, C. M., Bronte, V., Damuzzo, V., Gouttefangeas, C., Maurer, D., Ottensmeier, C. H. H., van der Burg, S. H., Welters, M. J. P., et al. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1782-5 · Cited by 202 · see citing works
Self-citationBeury, D. W., Parker, K. H., Nyandjo, M., Sinha, P., Carter, K. A., & Ostrand‐Rosenberg, S. (2014) · Journal of Leukocyte Biology · doi:10.1189/jlb.3a0414-210r · Cited by 183 · see citing works
Self-citationAptamer-Mediated Blockade of IL4Rα Triggers Apoptosis of MDSCs and Limits Tumor Progression
Roth, F., Fuente, A. C. D. L., Vella, J. L., Zoso, A., Inverardi, L., & Serafini, P. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2772 · Cited by 173 · see citing works
Haverkamp, J. M., Smith, A. M., Weinlich, R., Dillon, C. P., Qualls, J. E., Neale, G. A. M., Koss, B. S., Kim, Y., Bronte, V., Herold, M. J., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.020 · Cited by 167 · see citing works
Self-citationmiR-142-3p Prevents Macrophage Differentiation during Cancer-Induced Myelopoiesis
Sonda, N., Simonato, F., Peranzoni, E., Calì, B., Bortoluzzi, S., Bisognin, A., Wang, E., Marincola, F. M., Naldini, L., Gentner, B., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.06.004 · Cited by 140 · see citing works
Self-citationThe diversity of circulating neutrophils in cancer
Mishalian, I., Granot, Z., & Fridlender, Z. G. (2016) · Immunobiology · doi:10.1016/j.imbio.2016.02.001 · Cited by 140 · see citing works
Sumida, K., Wakita, D., Narita, Y., Masuko, K., Terada, S., Watanabe, K., Satoh, T., Kitamura, H., & Nishimura, T. (2012) · European Journal of Immunology · doi:10.1002/eji.201142335 · Cited by 126 · see citing works
Koehn, B. H., Apostolova, P., Haverkamp, J. M., Miller, J. S., McCullar, V., Tolar, J., Munn, D. H., Murphy, W. J., Brickey, W. J., Serody, J. S., et al. (2015) · Blood · doi:10.1182/blood-2015-03-634691 · Cited by 117 · see citing works
Self-citationBozkus, C. C., Elzey, B. D., Crist, S. A., Ellies, L. G., & Ratliff, T. L. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500959 · Cited by 112 · see citing works
Myeloid-Derived Suppressor Cells in the Development of Lung Cancer
Ortiz, M. L., Lu, L. D., Ramachandran, I., & Gabrilovich, D. I. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0129 · Cited by 110 · see citing works
Self-citationTrellakis, S., Bruderek, K., Hütte, J., Elian, M., Hoffmann, T. K., Lang, S., & Brandau, S. (2012) · Innate Immunity · doi:10.1177/1753425912463618 · Cited by 96 · see citing works
Self-citationHongo, D., Tang, X., Baker, J. B., Engleman, E. G., & Strober, S. (2014) · American Journal of Transplantation · doi:10.1111/ajt.12914 · Cited by 73 · see citing works
Li, Y., Tu, Z., Qian, S., Fung, J. J., Markowitz, S. D., Kusner, L. L., Kaminski, H. J., Lü, L., & Lin, F. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400857 · Cited by 65 · see citing works
Brusa, D., Simone, M., Gontero, P., Spadi, R., Racca, P., Micari, J., Degiuli, M., Carletto, S., Tizzani, A., & Matera, L. (2013) · International Journal of Urology · doi:10.1111/iju.12086 · Cited by 63 · see citing works
Myeloid-derived suppressor cells in mammary tumor progression in FVB Neu transgenic mice
Abe, F., Dafferner, A. J., Donkor, M. K., Westphal, S. N., Scholar, E. M., Solheim, J. C., Singh, R. K., Hoke, T. A., & Talmadge, J. E. (2009) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-009-0719-2 · Cited by 53 · see citing works
Slow Disease Progression in a C57BL/6 Pten-Deficient Mouse Model of Prostate Cancer
Svensson, R. U., Haverkamp, J. M., Thedens, D. R., Cohen, M. B., Ratliff, T. L., & Henry, M. D. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.03.014 · Cited by 44 · see citing works
Mairhofer, D. G., Ortner, D., Tripp, C. H., Schaffenrath, S., Fleming, V., Heger, L., Komenda, K., Reider, D., Dudziak, D., Chen, S., et al. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2015.241 · Cited by 28 · see citing works
Self-citationRigamonti, N., Capuano, G., Ricupito, A., Jachetti, E., Grioni, M., Generoso, L., Freschi, M., & Bellone, M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2547 · Cited by 27 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Tumour-associated macrophages as treatment targets in oncology
Mantovani, A., Marchesi, F., Malesci, A., Laghi, L., & Allavena, P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.217 · Cited by 4,065 · see citing works
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
de Visser, K. E., & Joyce, J. A. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.02.016 · Cited by 4,059 · see citing works
The Tumor Microenvironment Innately Modulates Cancer Progression
Hinshaw, D. C., & Shevde, L. A. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3962 · Cited by 3,270 · see citing works
The immune contexture in cancer prognosis and treatment
Fridman, W. H., Zitvogel, L., Sautès–Fridman, C., & Kroemer, G. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.101 · Cited by 2,263 · see citing works
Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment
Azizi, E., Carr, A. J., Plitas, G., Cornish, A. E., Konopacki, C., Prabhakaran, S., Nainys, J., Wu, K., Kiseliovas, V., Setty, M., et al. (2018) · Cell · doi:10.1016/j.cell.2018.05.060 · Cited by 1,976 · see citing works
Tumor angiogenesis: causes, consequences, challenges and opportunities
Lugano, R., Ramachandran, M., & Dimberg, A. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03351-7 · Cited by 2,040 · see citing works
Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity
Veglia, F., Sanseviero, E., & Gabrilovich, D. I. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-020-00490-y · Cited by 1,940 · see citing works
Self-citationMyeloid-Derived Suppressor Cells
Gabrilovich, D. I. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0297 · Cited by 1,890 · see citing works
Self-citationTumor-Associated Macrophages in Tumor Immunity
Pan, Y., Yu, Y., Wang, X., & Zhang, T. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.583084 · Cited by 1,884 · see citing works
Myeloid-derived suppressor cells coming of age
Veglia, F., Perego, M., & Gabrilovich, D. I. (2018) · Nature Immunology · doi:10.1038/s41590-017-0022-x · Cited by 1,774 · see citing works
Self-citationThe immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy
Bruni, D., Angell, H. K., & Galon, J. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-0285-7 · Cited by 1,586 · see citing works
Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment
Schulte-Schrepping, J., Reusch, N., Paclik, D., Baßler, K., Schlickeiser, S., Zhang, B., Krämer, B., Krammer, T., Brumhard, S., Bonaguro, L., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.001 · Cited by 1,461 · see citing works
Neutrophil diversity and plasticity in tumour progression and therapy
Jaillon, S., Ponzetta, A., Mitri, D. D., Santoni, A., Bonecchi, R., & Mantovani, A. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-0281-y · Cited by 1,298 · see citing works
Kim, N., Kim, H. K., Lee, K., Hong, Y., Cho, J. H., Choi, J. W., Lee, J.-I., Suh, Y., Ku, B. M., Eum, H. H., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16164-1 · Cited by 1,290 · see citing works
Immune checkpoint therapy—current perspectives and future directions
Sharma, P., Goswami, S., Raychaudhuri, D., Siddiqui, B. A., Singh, P., Nagarajan, A., Liu, J., Subudhi, S. K., Poon, C., Gant, K. L., et al. (2023) · Cell · doi:10.1016/j.cell.2023.03.006 · Cited by 1,206 · see citing works
Multimodal Analysis of Composition and Spatial Architecture in Human Squamous Cell Carcinoma
Ji, A. L., Rubin, A. J., Thrane, K., Jiang, S., Reynolds, D. L., Meyers, R. M., Guo, M. G., George, B. M., Mollbrink, A., Bergenstråhle, J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.039 · Cited by 1,117 · see citing works
Tumour-associated neutrophils in patients with cancer
Shaul, M. E., & Fridlender, Z. G. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0222-4 · Cited by 1,044 · see citing works
Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy
Cannarile, M. A., Weisser, M., Jacob, W., Jegg, A.-M., Ries, C. H., & Rüttinger, D. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0257-y · Cited by 1,029 · see citing works
Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer
Li, K., Shi, H., Zhang, B., Ou, X., Ma, Q., Chen, Y., Shu, P., Li, D., & Wang, Y.-S. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00670-9 · Cited by 914 · see citing works
Developmental and Functional Heterogeneity of Monocytes
Guilliams, M., Mildner, A., & Yona, S. (2018) · Immunity · doi:10.1016/j.immuni.2018.10.005 · Cited by 973 · see citing works
Lineage-dependent gene expression programs influence the immune landscape of colorectal cancer
Lee, H., Hong, Y., Etlioglu, H. E., Cho, Y. B., Pomella, V., den Bosch, B. V., Vanhecke, J., Verbandt, S., Hong, H.-K., Min, J.-W., et al. (2020) · Nature Genetics · doi:10.1038/s41588-020-0636-z · Cited by 916 · see citing works
Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression
Groth, C., Hu, X., Weber, R., Fleming, V., Altevogt, P., Utikal, J. S., & Umansky, V. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0333-1 · Cited by 846 · see citing works
Self-citationA pan-cancer blueprint of the heterogeneous tumor microenvironment revealed by single-cell profiling
Qian, J., Olbrecht, S., Boeckx, B., Vos, H., Laoui, D., Etlioglu, E., Wauters, E., Pomella, V., Verbandt, S., Busschaert, P., et al. (2020) · Cell Research · doi:10.1038/s41422-020-0355-0 · Cited by 818 · see citing works
Teijeira, Á., Garasa, S., Gato, M., Alfaro, C., Miguéliz, I., Cirella, A., de Andrea, C., Ochoa, M. C., Otano, I., Etxeberría, I., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.03.001 · Cited by 799 · see citing works
Neutrophils in cancer: heterogeneous and multifaceted
Hedrick, C. C., & Malanchi, I. (2021) · Nature reviews. Immunology · doi:10.1038/s41577-021-00571-6 · Cited by 778 · see citing works
Cell Adhesion Molecules and Their Roles and Regulation in the Immune and Tumor Microenvironment
Harjunpää, H., Asens, M. L., Guenther, C., & Fagerholm, S. C. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01078 · Cited by 758 · see citing works
Genetics and biology of prostate cancerPreprint
Wang, G., Zhao, D., Spring, D. J., & DePinho, R. A. (2018) · Genes & Development · doi:10.1101/gad.315739.118 · Cited by 758 · see citing works
Gut microbiota in colorectal cancer development and therapy
Wong, C. C., & Yu, J. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00766-x · Cited by 751 · see citing works
Monteran, L., & Erez, N. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01835 · Cited by 675 · see citing works
MDSC: Markers, development, states, and unaddressed complexity
Hegde, S., Leader, A. M., & Mérad, M. (2021) · Immunity · doi:10.1016/j.immuni.2021.04.004 · Cited by 672 · see citing works
Fridman, W. H., Meylan, M., Petitprez, F., Sun, C., Italiano, A., & Sautès‐Fridman, C. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00619-z · Cited by 667 · see citing works
Neutrophils as emerging therapeutic targets
Németh, T., Sperandio, M., & Mócsai, A. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0054-z · Cited by 657 · see citing works
The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma
Donné, R., & Lujambio, A. (2022) · Hepatology · doi:10.1002/hep.32740 · Cited by 651 · see citing works
Tang, T., Huang, X., Zhang, G., Hong, Z., Bai, X., & Liang, T. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00449-4 · Cited by 613 · see citing works
Cancer acidity: An ultimate frontier of tumor immune escape and a novel target of immunomodulation
Huber, V., Camisaschi, C., Berzi, A., Ferro, S., Lugini, L., Triulzi, T., Tuccitto, A., Tagliabue, E., Castelli, C., & Rivoltini, L. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.03.001 · Cited by 595 · see citing works
Cancer stem cells: advances in knowledge and implications for cancer therapy
Chu, X., Tian, W., Ning, J., Xiao, G., Zhou, Y., Wang, Z., Zhai, Z., Tanzhu, G., Yang, J., & Zhou, R. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01851-y · Cited by 597 · see citing works
Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets
Tie, Y., Tang, F., Wei, Y.-Q., & Wei, X.-W. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01282-8 · Cited by 591 · see citing works
Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors
Weber, R., Fleming, V., Hu, X., Nagibin, V. S., Groth, C., Altevogt, P., Utikal, J. S., & Umansky, V. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01310 · Cited by 535 · see citing works
Self-citationAlshetaiwi, H. S., Pervolarakis, N., McIntyre, L. L., Ma, D., Nguyen, Q., Rath, J. A., Nee, K., Hernandez, G. A., Evans, K. T., Torosian, L., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.aay6017 · Cited by 521 · see citing works
Neutrophil Diversity in Health and Disease
Silvestre-Roig, C., Fridlender, Z. G., Glogauer, M., & Scapini, P. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.04.012 · Cited by 531 · see citing works
Myeloid immunosuppression and immune checkpoints in the tumor microenvironment
Nakamura, K., & Smyth, M. J. (2019) · Cellular and Molecular Immunology · doi:10.1038/s41423-019-0306-1 · Cited by 521 · see citing works
Ostrand-Rosenberg, S., & Fenselau, C. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701019 · Cited by 509 · see citing works
Self-citationMyeloid-derived suppressor cells in cancer and cancer therapy
Lasser, S., Kurt, F. G. Ö., Arkhypov, I., Utikal, J. S., & Umansky, V. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00846-y · Cited by 514 · see citing works
Self-citationOrth, M., Metzger, P., Gerum, S., Mayerle, J. V., Schneider, G., Belka, C., Schnurr, M., & Lauber, K. (2019) · Radiation Oncology · doi:10.1186/s13014-019-1345-6 · Cited by 488 · see citing works
Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy
Wu, Y., Yi, M., Niu, M., Mei, Q., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01657-y · Cited by 463 · see citing works
Oh, M.-H., Sun, I.-H., Zhao, L., Leone, R. D., Sun, I.-M., Xu, W., Collins, S. L., Tam, A. J., Blosser, R. L., Patel, C. H., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci131859 · Cited by 456 · see citing works
Neutrophils in cancer: prognostic role and therapeutic strategies
Ocaña, A., Nieto‐Jiménez, C., Pandiella, A., & Templeton, A. J. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0707-7 · Cited by 460 · see citing works
Targeted deletion of PD-1 in myeloid cells induces antitumor immunity
Strauss, L., Mahmoud, M. A. A., Weaver, J. D., Tijaro-Ovalle, N. M., Christofides, A., Wang, Q., Pal, R., Yuan, M., Asara, J., Patsoukis, N., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.aay1863 · Cited by 437 · see citing works
Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression
Fleming, V., Hu, X., Weber, R., Nagibin, V. S., Groth, C., Altevogt, P., Utikal, J. S., & Umansky, V. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00398 · Cited by 444 · see citing works
Self-citationThe Role of Myeloid-Derived Suppressor Cells (MDSC) in Cancer Progression
Umansky, V., Blattner, C., Gebhardt, C., & Utikal, J. S. (2016) · Vaccines · doi:10.3390/vaccines4040036 · Cited by 440 · see citing works
Self-citationMyeloid Cell-Derived Arginase in Cancer Immune Response
Grzywa, T. M., Sosnowska, A., Matryba, P., Rydzyńska, Z., Jasiński, M., Nowis, D., & Gołąb, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00938 · Cited by 434 · see citing works
Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer
Law, A. M. K., Valdes-Mora, F., & Gallego-Ortega, D. (2020) · Cells · doi:10.3390/cells9030561 · Cited by 455 · see citing works
Plasticity of myeloid-derived suppressor cells in cancer
Tcyganov, E., Mastio, J., Chen, E., & Gabrilovich, D. I. (2018) · Current Opinion in Immunology · doi:10.1016/j.coi.2018.03.009 · Cited by 398 · see citing works
Neutrophils dominate the immune cell composition in non-small cell lung cancer
Kargl, J., Busch, S., Yang, G. H. Y., Kim, K.-H., Hanke, M. L., Metz, H. E., Hubbard, J. J., Lee, S. M., Madtes, D. K., McIntosh, M. W., et al. (2017) · Nature Communications · doi:10.1038/ncomms14381 · Cited by 412 · see citing works
Paradigms on Immunotherapy Combinations with Chemotherapy
Salas‐Benito, D., Perez‐Gracia, J. L., Ponz‐Sarvisé, M., Rodriguez-Ruiz, M. E., Martínez‐Forero, I., Álvarez, E. C., López-Picazo, J. M., Sanmamed, M. F., & Melero, I. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1312 · Cited by 401 · see citing works
Neutrophils in Homeostasis, Immunity, and Cancer
Nicolás-Ávila, J. Á., Adrover, J. M., & Hidalgo, A. (2017) · Immunity · doi:10.1016/j.immuni.2016.12.012 · Cited by 407 · see citing works
Il-23 secreted by myeloid cells drives castration-resistant prostate cancer
Calcinotto, A., Spataro, C., Zagato, E., Di Mitri, D., Gil, V., Crespo, M., De Bernardis, G., Losa, M., Mirenda, M., Pasquini, E., et al. (2018) · Nature · doi:10.1038/s41586-018-0266-0 · Cited by 394 · see citing works
The CCL5/CCR5 Axis in Cancer Progression
Aldinucci, D., Borghese, C., & Casagrande, N. (2020) · Cancers · doi:10.3390/cancers12071765 · Cited by 413 · see citing works
Deterministic reprogramming of neutrophils within tumors
Ng, M. S. F., Kwok, I., Tan, L., Shi, C., Cerezo‐Wallis, D., Tan, Y., Leong, K. W. K., Calvo, G. F., Yang, K. L., Zhang, Y., et al. (2024) · Science · doi:10.1126/science.adf6493 · Cited by 400 · see citing works
Regulation of PD-L1 Expression by NF-κB in Cancer
Antonangeli, F., Natalini, A., Garassino, M. C., Sica, A., Santoni, A., & Rosa, F. D. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.584626 · Cited by 388 · see citing works
Self-citation<scp>IL</scp>‐1 and <scp>IL</scp>‐1 regulatory pathways in cancer progression and therapy
Mantovani, A., Barajon, I., & Garlanda, C. (2018) · Immunological Reviews · doi:10.1111/imr.12614 · Cited by 376 · see citing works
Current gaps in sepsis immunology: new opportunities for translational research
Rubio, I., Osuchowski, M. F., Shankar‐Hari, M., Skirecki, T., Winkler, M. S., Lachmann, G., Rosée, P. G. L., Monneret, G., Venet, F., Bauer, M. W., et al. (2019) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(19)30567-5 · Cited by 380 · see citing works
Orillion, A., Hashimoto, A., Damayanti, N., Shen, L., Adelaiye-Ogala, R., Arisa, S., Chintala, S., Ordentlich, P., Kao, C., Elzey, B., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0741 · Cited by 373 · see citing works
Self-citationWang, H., Tian, T., & Zhang, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168470 · Cited by 364 · see citing works
Nanoparticles in tumor microenvironment remodeling and cancer immunotherapy
Lü, Q., Kou, D., Lou, S., Ashrafizadeh, M., Aref, A. R., Cañadas, I., Tian, Y., Niu, X., Wang, Y. Z., Torabian, P., et al. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01535-8 · Cited by 376 · see citing works
Tumor Immune Microenvironment during Epithelial–Mesenchymal Transition
Taki, M., Abiko, K., Ukita, M., Murakami, R., Yamanoi, K., Yamaguchi, K. D., Hamanishi, J., Baba, T., Matsumura, N., & Mandai, M. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4459 · Cited by 357 · see citing works
Neutrophil Degranulation, Plasticity, and Cancer Metastasis
Mollinedo, F. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.01.006 · Cited by 353 · see citing works
Al-Khami, A. A., Zheng, L., Valle, L. D., Hossain, F. M., Wyczechowska, D. D., Zabaleta, J., Sanchez‐Pino, M. D., Dean, M. J., Rodrı́guez, P. C., & Ochoa, A. C. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1344804 · Cited by 348 · see citing works
Self-citationp53, cancer and the immune response
Blagih, J., Buck, M. D., & Vousden, K. H. (2020) · Journal of Cell Science · doi:10.1242/jcs.237453 · Cited by 333 · see citing works
Understanding the tumor microenvironment for effective immunotherapy
Sadeghi Rad, H., Monkman, J., Warkiani, M. E., Ladwa, R., O'Byrne, K., Rezaei, N., & Kulasinghe, A. (2021) · Medicinal Research Reviews · doi:10.1002/med.21765 · Cited by 334 · see citing works
Neutrophil phenotypes and functions in cancer: A consensus statement
Quail, D. F., Amulic, B., Aziz, M., Barnes, B. J., Eruslanov, E. B., Fridlender, Z. G., Goodridge, H. S., Granot, Z., Hidalgo, A., Anna Huttenlocher, A., et al. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20220011 · Cited by 336 · see citing works
Neutrophils and PMN-MDSC: Their biological role and interaction with stromal cells
Zhou, J., Nefedova, Y., Lei, A., & Gabrilovich, D. I. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.12.004 · Cited by 343 · see citing works
Self-citationCicco, P. D., Ercolano, G., & Ianaro, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01680 · Cited by 338 · see citing works
Kim, I. S., Gao, Y., Welte, T., Wang, H., Liu, J., Janghorban, M., Sheng, K., Niu, Y., Goldstein, A., Zhao, N., et al. (2019) · Nature Cell Biology · doi:10.1038/s41556-019-0373-7 · Cited by 334 · see citing works
Chen, B., Scurrah, C. R., McKinley, E. T., Simmons, A. J., Ramirez-Solano, M. A., Zhu, X., Markham, N. O., Heiser, C. N., Vega, P. N., Rolong, A., et al. (2021) · Cell · doi:10.1016/j.cell.2021.11.031 · Cited by 328 · see citing works
Mohammadpour, H., MacDonald, C. R., Qiao, G., Chen, M., Dong, B., Hylander, B. L., McCarthy, P. L., Abrams, S. I., & Repasky, E. A. (2019) · Journal of Clinical Investigation · doi:10.1172/jci129502 · Cited by 328 · see citing works
Vernieri, C., Fucà, G., Ligorio, F., Huber, V., Vingiani, A., Iannelli, F., Raimondi, A., Rinchai, D., Frigè, G., Belfiore, A., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0030 · Cited by 319 · see citing works
Self-citationКологривова, И. В., Штатолкина, М. А., Суслова, Т. Е., & Ryabov, V. V. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.664457 · Cited by 319 · see citing works
Macrophage Polarity and Disease Control
Kadomoto, S., Izumi, K., & Mizokami, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010144 · Cited by 319 · see citing works
Tumor-associated macrophages in cancer: recent advancements in cancer nanoimmunotherapies
Kumari, N., & Choi, S. H. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02272-x · Cited by 324 · see citing works
Durable anticancer immunity from intratumoral administration of IL-23, IL-36γ, and OX40L mRNAs
Hewitt, S. L., Bai, A., Bailey, D., Ichikawa, K., Zielinski, J., Karp, R., Apte, A., Arnold, K., Zacharek, S. J., Iliou, M. S., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aat9143 · Cited by 316 · see citing works
The Role of Tumor-Associated Neutrophils in Colorectal Cancer
Mizuno, R., Kawada, K., Itatani, Y., Ogawa, R., Kiyasu, Y., & Sakai, Y. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030529 · Cited by 318 · see citing works
Monocytes in the Tumor Microenvironment
Ugel, S., Canè, S., Sanctis, F. D., & Bronte, V. (2021) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-012418-013058 · Cited by 316 · see citing works
Self-citationTumor-associated neutrophils and neutrophil-targeted cancer therapies
Que, H., Fu, Q., Lan, T., Tian, X., & Wei, X. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188762 · Cited by 319 · see citing works
Veglia, F., Hashimoto, A., Dweep, H., Sanseviero, E., Leo, A. D., Tcyganov, E. N., Kossenkov, A. V., Mulligan, C. G., Nam, B. T., Masters, G. A., et al. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20201803 · Cited by 314 · see citing works
Self-citationIL-6 as a major regulator of MDSC activity and possible target for cancer immunotherapy
Weber, R., Groth, C., Lasser, S., Arkhypov, I., Petrova, V., Altevogt, P., Utikal, J. S., & Umansky, V. (2020) · Cellular Immunology · doi:10.1016/j.cellimm.2020.104254 · Cited by 310 · see citing works
Self-citationDifferential effects on lung and bone metastasis of breast cancer by Wnt signalling inhibitor DKK1
Zhuang, X., Zhang, H., Li, X., Li, X., Cong, M., Peng, F., Yu, J., Zhang, X., Yang, Q., & Hu, G. (2017) · Nature Cell Biology · doi:10.1038/ncb3613 · Cited by 309 · see citing works
Human neutrophils: Their role in cancer and relation to myeloid-derived suppressor cells
Moses, K., & Brandau, S. (2016) · Seminars in Immunology · doi:10.1016/j.smim.2016.03.018 · Cited by 306 · see citing works
Self-citationmiR200-regulated CXCL12β promotes fibroblast heterogeneity and immunosuppression in ovarian cancers
Givel, A.-M., Kieffer, Y., Scholer-Dahirel, A., Sirven, P., Cardon, M., Pelon, F., Magagna, I., Gentric, G., Costa, A., Bonneau, C., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03348-z · Cited by 295 · see citing works
Therapeutic targeting of tumour myeloid cells
Barry, S. T., Gabrilovich, D. I., Sansom, O. J., Campbell, A. D., & Morton, J. P. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00546-2 · Cited by 305 · see citing works
Self-citationCAR-T cell therapy for cancer: current challenges and future directions
Zugasti, I., Espinosa-Aroca, L., Fidyt, K., Mulens‐Arias, V., Díaz‐Beyá, M., Juan, M., Urbano-Ispizúa, Á., Esteve, J., Velasco-Hernández, T., & Menéndez, P. R. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02269-w · Cited by 332 · see citing works
Haist, M., Stege, H., Grabbe, S., & Bros, M. (2021) · Cancers · doi:10.3390/cancers13020210 · Cited by 295 · see citing works
Single-cell RNA sequencing reveals evolution of immune landscape during glioblastoma progression
Yeo, A. T., Rawal, S., Delcuze, B., Christofides, A., Atayde, A. M. P., Strauss, L., Balaj, L., Rogers, V. A., Uhlmann, E. J., Varma, H., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01215-0 · Cited by 294 · see citing works
Targeted and Immune-Based Therapies for Hepatocellular Carcinoma
Greten, T. F., Lai, C. W., Li, G., & Staveley-O’Carroll, K. F. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.09.051 · Cited by 293 · see citing works
Self-citationYang, Y., Li, C., Liu, T., Dai, X., & Bazhin, A. V. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01371 · Cited by 294 · see citing works
Arginine Metabolism in Myeloid Cells Shapes Innate and Adaptive Immunity
Rodrı́guez, P. C., Ochoa, A. C., & Al-Khami, A. A. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00093 · Cited by 287 · see citing works
Self-citationGreene, S., Robbins, Y., Mydlarz, W. K., Huynh, A. P., Schmitt, N. C., Friedman, J., Horn, L. A., Palena, C., Schlom, J., Maeda, D. Y., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2625 · Cited by 280 · see citing works
MDSCs: Key Criminals of Tumor Pre-metastatic Niche Formation
Wang, Y., Ding, Y., Guo, N., & Wang, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00172 · Cited by 282 · see citing works
Relevance of immune cell and tumor microenvironment imaging in the new era of immunotherapy
Galli, F., Aguilera, J. V., Palermo, B., Markovic, S. N., Nisticò, P., & Signore, A. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01586-y · Cited by 281 · see citing works
Kitamura, H., Ohno, Y., Toyoshima, Y., Ohtake, J., Homma, S., Kawamura, H., Takahashi, N., & Taketomi, A. (2017) · Cancer Science · doi:10.1111/cas.13332 · Cited by 278 · see citing works
- Authors
- Bronte, V., Brandau, S., Chen, S.-H., Colombo, M. P., Frey, A. B., Greten, T. F., Mandruzzato, S., Murray, P. J., Ochoa, A., Ostrand-Rosenberg, S., Rodriguez, P. C., Sica, A., Umansky, V., Vonderheide, R. H., & Gabrilovich, D. I.
- Affiliations
- University of Verona (IT)
- Essen University Hospital (DE)
- Tisch Cancer Institute (US)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- New York University (US)
- National Cancer Institute (US)
- University of Padua (IT)
- St. Jude Children's Research Hospital (US)
- Louisiana State University (US)
- Università degli Studi del Piemonte Orientale “Amedeo Avogadro” (IT)
- German Cancer Research Center (DE)
- Abramson Cancer Center (US)
- The Wistar Institute (US)
- Corresponding author
- Bronte, Vincenzo
- Gabrilovich, Dmitry I.
- ORCID
- Venue
- Nature Communications
- Published
- 2016-07-06
- Volume
- 7
- Issue
- 1
- Pages
- 12150-12150
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC4935811
- OpenAlex
- W2471500324
- Cited by
- 2,751
- References
- 81
- Citations by year
- 2026: 194 · 2025: 234 · 2024: 312 · 2023: 300 · 2022: 331 · 2021: 370 · 2020: 330 · 2019: 255 · 2018: 238 · 2017: 157 · 2016: 25 · 2012: 1
- FWCI
- 21.70
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Maryland Shared Open Access Repository (USMAI Consortium) (submittedVersion, cc-by)
- Padua Research Archive (University of Padova) (submittedVersion, other-oa)
- Digital Repository at the University of Maryland (University of Maryland College Park) (cc-by)
- Funders
- St. Jude Children's Research Hospital (CA21765)
- Deutsches Krebsforschungszentrum (CA157)
- American Lebanese Syrian Associated Charities (P30CA21765, CA 21765)
- Deutsche Forschungsgemeinschaft (BM1404)
- Ministero della Salute
- Ministero dell’Istruzione, dell’Università e della Ricerca (RBAP11H2R9_005, B31J11000420001)
- Associazione Italiana per la Ricerca sul Cancro (12886, 12182, 14103, 15585, 14194, AIRC 6599)
- National Institutes of Health (GM 021248, CA21765))
- National Heart, Lung, and Blood Institute (R01HL056067)
- National Cancer Institute (R01CA204191, R01CA084488, R01CA109322, R01CA127483, R01CA184185, R01CA141438, R01CA100062, P30CA021765, P30CA010815, R01CA115880)
- National Institute of General Medical Sciences (R37GM021248, R01GM021248)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › Phagocytosis and Immune Regulation
- Keywords
- myeloid-derived suppressor cells, nomenclature, tumor immunology, immunosuppression, tumor progression, phenotypic heterogeneity, inflammation
- MeSH terms
- Myeloid-Derived Suppressor Cells, Algorithms, Animals, Cell Differentiation, Humans, Neoplasms, Terminology as Topic, Antigens, CD, Cytokines, Models, Immunological
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
